Jacobus Pharmaceutical Company, Inc.
USPTO PatentsView assignee record - 5 granted patents across 6 technology areas, recorded in grant years 2015–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Jacobus ranks #47,897 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 6 technology areas.
- #47,897
- of 49,997 US assignees by volume
- 13th percentile
- by Innovation Score (23.6/100)
- 14.6
- avg claims per patent
- -75%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R47897 · US Corporation #47,897 · 5 grants
GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 5 grants
- BOTTOM-DECILE #47,897/49,997
- PHOTO-FINISH J Hench Consulting
- CPC-NARROW C07D · 6 areas
- INNOV-THIN 23.6/100
- CLAIMS-RICH 14.6 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -75% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: J. Hench Consulting, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Jacobus’s 23.6 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Jacobus
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Jacobus Pharmaceutical · this assignee 24
Jacobus Pharmaceutical · this assignee
24 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Jacobus's Innovation Score is 23.6/100 (13th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Jacobus?
Each dot is one of Jacobus’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Jacobus’s own 14.6 claims/patent is ABOVE the 14.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Jacobus's grants concentrate
Jacobus Pharmaceutical Company, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2015. By volume, Jacobus sits between J. Hench Consulting, Inc. and Janibell, Inc..
Who files at Jacobus's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- J Hench Consulting
J. Hench Consulting, Inc.
5 patents
- J M Canty
J.M. Canty Inc.
5 patents
- Jackson Kayak
Jackson Kayak, Inc.
5 patents
- Jacob Jensen Desi…
Jacob Jensen Design A/S
5 patents
- Jagtech AS
Jagtech AS
5 patents
- JAM Packaging
JAM Packaging LLC
5 patents
- Jamm
Jamm Technologies, Inc.
5 patents
- Janibell
Janibell, Inc.
5 patents
- Jacobus Pharmaceu… ◀
Jacobus Pharmaceutical Company, Inc.
5 patents
What this shows Jacobus holds 5 patents at rank #47,899, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Jacobus
By rank, the assignees closest to #47,899 in granted patent volume.
- J. Hench Consulting, Inc. #47,895 · 5 patents
- J.M. Canty Inc. #47,896 · 5 patents
- Jackson Kayak, Inc. #47,897 · 5 patents
- Jacob Jensen Design A/S #47,898 · 5 patents
- Jagtech AS #47,900 · 5 patents
- JAM Packaging LLC #47,901 · 5 patents
- Jamm Technologies, Inc. #47,902 · 5 patents
- Janibell, Inc. #47,903 · 5 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in Jacobus's primary technology class.
Jacobus's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
24 13th percentile higher than 13% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 20.0% |
| 2016 | 2 | 40.0% |
| 2017 | 1 | 20.0% |
| 2020 | 1 | 20.0% |
Which technologies does Jacobus Pharmaceutical Company, Inc. patent most?
Top 6 of 6 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Jacobus Pharmaceutical Company, Inc.'s patent record in context - here's where to go next.
- Jacobus Pharmaceutical Company, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #47,897 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Jacobus Pharmaceutical Company, Inc. against J. Hench Consulting, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 23.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.